Skip to main content
Erschienen in: World Journal of Surgery 12/2010

01.12.2010

Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction

verfasst von: John V. Reynolds, Narayanasamy Ravi, Cian Muldoon, John O. Larkin, Suzanne Rowley, Ken O’Byrne, Donal Hollywood, Dermot O’Toole

Erschienen in: World Journal of Surgery | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Adenocarcinoma of the esophagogastric junction (AEG) as described by Siewert et al. is classified as one entity in the latest (7th Edition) American Joint Cancer Committee/International Union Against Cancer (AJCC/UICC) manual, compared with the previous mix of esophageal and gastric staging systems. The origin of AEG tumors, esophageal or gastric, and their biology remain controversial, particularly for AEG type II (cardia) tumors.

Methods

We adapted a large prospective database (n = 520: 180 type I, 182 type II, 158 type III) to compare AEG tumors under the new TNM system Pathological variables associated with prognosis were compared (pT, pN, stage, differentiation, R status, lymphovascular invasion, perineural involvement, number of positive nodes, percent of positive nodes, and tumor length), as well as overall survival.

Results

Compared with AEG type I tumors, type II and type III tumors had significantly (p < 0.05) more advanced pN stages, greater number and percentage of positive nodes, poorer differentiation, more radial margin involvement, and more perineural invasion. In AEG type I, 14/180 patients (8%) had >6 involved nodes (pN3), compared with 16 and 30% of patients classified type II and III, respectively. Median survival was significantly (p = 0.03) improved for type I patients (38 months) compared with those with tumors classified as type II (28 months) and type III (24 months). In multivariate analysis node positivity and pN staging but not AEG site had an impact on survival.

Conclusions

In this series AEG type I is associated with more favorable pathologic features and improved outcomes compared with AEG type II and III. This may reflect earlier diagnosis, but an alternative possibility, that type I may be a unique paradigm with more favorable biology, requires further study.
Literatur
1.
Zurück zum Zitat Forman D (2004) Oesophago-gastric adenocarcinoma—an epidemiological perspective. Aliment Pharmacol Ther 20(Suppl 5):55–60CrossRefPubMed Forman D (2004) Oesophago-gastric adenocarcinoma—an epidemiological perspective. Aliment Pharmacol Ther 20(Suppl 5):55–60CrossRefPubMed
2.
Zurück zum Zitat Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053CrossRefPubMed Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053CrossRefPubMed
3.
Zurück zum Zitat Siewert JR, Feith M, Werner M et al (2000) Adenocarcinoma of the esophagastric junction: results of surgical therapy based on anatomical/topographical classification in 1002 consecutive patients. Ann Surg 232:353–361CrossRef Siewert JR, Feith M, Werner M et al (2000) Adenocarcinoma of the esophagastric junction: results of surgical therapy based on anatomical/topographical classification in 1002 consecutive patients. Ann Surg 232:353–361CrossRef
4.
Zurück zum Zitat Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophago-gastric junction. Br J Surg 85:1457–1459CrossRefPubMed Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophago-gastric junction. Br J Surg 85:1457–1459CrossRefPubMed
5.
Zurück zum Zitat Humagilli U (1996) Resective surgery for cancer of the thoracic esophagus. Results of a consensus conference of the International Society for Diseases of the Esophagus. Dis Esophagus 9(Suppl 1):30–38 Humagilli U (1996) Resective surgery for cancer of the thoracic esophagus. Results of a consensus conference of the International Society for Diseases of the Esophagus. Dis Esophagus 9(Suppl 1):30–38
6.
Zurück zum Zitat American Joint Committee on Cancer (2002) AJCC cancer staging manual, 6th edn. Springer, New York American Joint Committee on Cancer (2002) AJCC cancer staging manual, 6th edn. Springer, New York
7.
Zurück zum Zitat American Joint Committee on Cancer (2009) AJCC cancer staging manual, 7th edn. Springer, New York American Joint Committee on Cancer (2009) AJCC cancer staging manual, 7th edn. Springer, New York
8.
Zurück zum Zitat Sobin LH, Gospodarowicz M, Wittekind C (2009) TMN classification of malignant tumours, 7th edn. Wiley-Blackwell, London Sobin LH, Gospodarowicz M, Wittekind C (2009) TMN classification of malignant tumours, 7th edn. Wiley-Blackwell, London
9.
10.
Zurück zum Zitat Maher SG, Gillham CM, Duggan SP et al (2009) Gene expression analysis of diagnostic biopsies predicted pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 250:729–737CrossRefPubMed Maher SG, Gillham CM, Duggan SP et al (2009) Gene expression analysis of diagnostic biopsies predicted pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 250:729–737CrossRefPubMed
11.
Zurück zum Zitat Reynolds JV, Muldoon C, Hollywood D et al (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245:707–716CrossRefPubMed Reynolds JV, Muldoon C, Hollywood D et al (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 245:707–716CrossRefPubMed
12.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, MAGIC Trial Participants et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20CrossRefPubMed Cunningham D, Allum WH, Stenning SP, MAGIC Trial Participants et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20CrossRefPubMed
13.
Zurück zum Zitat Griffiths EA, Pritchard SA, Mapstone NP et al (2006) Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology—an update for the surgical oncologist. World J Surg Oncol 4:82–89CrossRefPubMed Griffiths EA, Pritchard SA, Mapstone NP et al (2006) Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology—an update for the surgical oncologist. World J Surg Oncol 4:82–89CrossRefPubMed
14.
Zurück zum Zitat Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73:2680–2686CrossRefPubMed Mandard AM, Dalibard F, Mandard JC et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer 73:2680–2686CrossRefPubMed
15.
Zurück zum Zitat Leers JM, De Meester SR, Chan N et al (2009) Clinical characteristics, biologic behaviour, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 138:594–602CrossRefPubMed Leers JM, De Meester SR, Chan N et al (2009) Clinical characteristics, biologic behaviour, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 138:594–602CrossRefPubMed
16.
Zurück zum Zitat Siewert JR, Feith M (2007) Adenocarcinoma of the esophagogastric junction: competition between Barrett and gastric cancer. J Am Coll Surg 205:S48–S53CrossRef Siewert JR, Feith M (2007) Adenocarcinoma of the esophagogastric junction: competition between Barrett and gastric cancer. J Am Coll Surg 205:S48–S53CrossRef
17.
Zurück zum Zitat Mattioli S, Ruffato A, Di Simone MP et al (2007) Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors. Ann Thorac Surg 83:1814–1819CrossRefPubMed Mattioli S, Ruffato A, Di Simone MP et al (2007) Immunopathological patterns of the stomach in adenocarcinoma of the esophagus, cardia, and gastric antrum: gastric profiles in Siewert type I and II tumors. Ann Thorac Surg 83:1814–1819CrossRefPubMed
18.
Zurück zum Zitat Cahu I, Norman AR, Cunningham D et al (2009) The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20:885–891CrossRef Cahu I, Norman AR, Cunningham D et al (2009) The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 20:885–891CrossRef
19.
Zurück zum Zitat Chandrasoma P, Wickramasinge K, Ma Y et al (2007) Adenocarcinoma of the distal esophagus and “gastric cardia” are predominantly esophageal adenocarcinomas. Am J Surg Pathol 31:569–575CrossRefPubMed Chandrasoma P, Wickramasinge K, Ma Y et al (2007) Adenocarcinoma of the distal esophagus and “gastric cardia” are predominantly esophageal adenocarcinomas. Am J Surg Pathol 31:569–575CrossRefPubMed
20.
Zurück zum Zitat Chandrasoma P, Makareticz K, Wickramasinge K et al (2006) A proposal for a new validated histologic definition of the gastroesophageal junction. Hum Pathol 37:40–47CrossRefPubMed Chandrasoma P, Makareticz K, Wickramasinge K et al (2006) A proposal for a new validated histologic definition of the gastroesophageal junction. Hum Pathol 37:40–47CrossRefPubMed
21.
Zurück zum Zitat Lagergren J, Bergstrom R, Lindgren A et al (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831CrossRefPubMed Lagergren J, Bergstrom R, Lindgren A et al (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831CrossRefPubMed
22.
Zurück zum Zitat Mariette C, Piessen G, Briez N et al (2008) The number of metastatic nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 247:365–371CrossRefPubMed Mariette C, Piessen G, Briez N et al (2008) The number of metastatic nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 247:365–371CrossRefPubMed
23.
Zurück zum Zitat Peyre CG, Hagen JA, De Meester SR et al (2008) The number of lymph nodes predicts survival in esophageal cancer: an international study on the extent of surgical resection. Ann Surg 248:549–556CrossRefPubMed Peyre CG, Hagen JA, De Meester SR et al (2008) The number of lymph nodes predicts survival in esophageal cancer: an international study on the extent of surgical resection. Ann Surg 248:549–556CrossRefPubMed
24.
Zurück zum Zitat Lamb PJ, Griffin SM, Burt AD et al (2005) Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. Br J Surg 92:60–67CrossRefPubMed Lamb PJ, Griffin SM, Burt AD et al (2005) Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. Br J Surg 92:60–67CrossRefPubMed
25.
Zurück zum Zitat Barbour AP, Rizk NP, Gonnen N et al (2007) Adenocarcinoma of the gastroesophageal junction: influence of surgical resection margin and operative approach on outcome. Ann Surg 246:1–8CrossRefPubMed Barbour AP, Rizk NP, Gonnen N et al (2007) Adenocarcinoma of the gastroesophageal junction: influence of surgical resection margin and operative approach on outcome. Ann Surg 246:1–8CrossRefPubMed
Metadaten
Titel
Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction
verfasst von
John V. Reynolds
Narayanasamy Ravi
Cian Muldoon
John O. Larkin
Suzanne Rowley
Ken O’Byrne
Donal Hollywood
Dermot O’Toole
Publikationsdatum
01.12.2010
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 12/2010
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-010-0783-y

Weitere Artikel der Ausgabe 12/2010

World Journal of Surgery 12/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.